Skip To Main Content
Ying-Ming Chiu on Muck Rack

Ying-Ming Chiu

As seen in: Arthritis & Rheumatology, Wiley Online Library, Frontiers in Public Health, Arthritis Research & Therapy, JAMA (The Journal of the American Medical Association), Journal of The American Academy of Dermatology (JAAD)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Ming

Contact Ying-Ming, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world costs per life-year of targeted therapy, incidence, lifetime health impact, and medical costs of renal cell carcinoma in Taiwan

|
By Min-Che Tung, Yen-Chuan Ou, Ying-Ming Chiu, Chia-Che Chang, Chin-Heng Lu, Siu-San Tse
| Frontiers in Public Health Verified
Abstract Background: The incidence of renal cell carcinoma (RCC) and its associated economic burden have risen significantly in Taiwan. While targeted therapy has become a standard treatment, its real-world effectiveness and cost-effectiveness remain to be fully evaluated. Methods: This population-based cohort study utilized the Taiwan National Health Insurance Research Database and Cancer Registry to analyze 14,131 RCC cases diagnosed between 1998 and 2016.
Open in Who Shared Issue with article?

Life Expectancy, Loss of Life Expectancy, and Lifetime Costs in Bipolar Disorder: A Nationwide Population‐Based Study

|
By Ikbal Andrian Malau, Ying-Ming Chiu, Management Miaoli Taiwan, Hui-Chih Chang
| Wiley Online Library Verified
Conflicts of Interest Prof Su has been a speaker and/or consultant for Johnson & Johnson, AstraZeneca, Lundbeck, Eli Lilly, Merck, Pfizer, Servier, Otsuka, Excelsior Biopharma, Chen Hua Biotech, Nutrarex Biotech, and Hoan Pharmaceuticals.
Open in Who Shared Issue with article?

Risk of Cardiovascular Morbidity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Survivors

|
By Hsien-Yi Chiu, Ying-Ming Chiu
| JAMA (The Journal of the American Medical Association) Verified
Risk of Cardiovascular Morbidity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Survivors Key Points Question What are the risks of cardiovascular morbidity and mortality in patients who survive Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) episodes compared to patients without SJS/TEN?
Open in Who Shared Issue with article?
See all 9 articles